ReviewFrontiers in neurology2025
The impact of the let-7 family on the pathophysiological mechanisms of traumatic brain injury: a systematic review.
Review in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Urinary Exosomal microRNAs as a Novel Approach to Study People with Multiple Sclerosis and Severe Gait Disability: A Preliminary Observation.Non-coding RNA · 2026Article
- Article
- ncRNAs in breast milk of mothers with SLE: potential implications for neonatal immune development.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The lethal-7 (let-7) family of microRNAs (miRNAs) plays a crucial role in regulating key biological functions, including cell differentiation, inflammation, metabolism, and proliferation. Their dysregulation has been implicated in various diseases, including cancer and neurological disorders. Despite extensive knowledge of their roles in normal physiology and disease, the involvement of let-7 miRNAs in the pathophysiology of traumatic brain injury (TBI) remains incompletely understood. Objective: To systematically identify and analyze the differential expression of let-7 family members following TBI across human and animal models and to assess their potential role as diagnostic biomarkers and therapeutic targets. Methods: A systematic review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Literature was retrieved from PubMed, EMBASE, and Web of Science using predefined keywords based on a PICO framework. Studies were included if they reported on let-7 family expression post-TBI in humans or animals. Risk of bias was assessed using the Evidence Project and SYRCLE tools. Data were extracted regarding species, sample type, TBI model, time points, and let-7 expression profiles. PROSPERO 2025 CRD420251129282. Available from https://www.crd.york.ac.uk/PROSPERO/view/CRD420251129282. Results: Out of 41 initially identified records, 15 studies met the inclusion criteria. In human studies, upregulation of let-7 family members (e.g., let-7a, b, c, f, i) was consistently observed in peripheral biofluids (serum, plasma, saliva) following mild to severe TBI. However, cerebrospinal fluid (CSF) levels showed mixed or decreased expression patterns. In contrast, animal studies have shown predominant downregulation of let-7 in brain tissues post-TBI, with some evidence suggesting their role in modulating neuroinflammatory responses, apoptosis, and energy metabolism. Let-7c and let-7i were particularly implicated in the modulation of microglial activation, IL-6 regulation, and STING signaling pathways. Limited mechanistic data suggest let7's involvement in glucose metabolism, N-acetylaspartate homeostasis, and antioxidant response. Conclusions: The let-7 family exhibits divergent expression trends in tissue and biofluids following TBI, highlighting their potential as non-invasive biomarkers. Their regulatory roles in inflammation, metabolism, and neuroprotection suggest therapeutic promise. However, current evidence remains fragmented, and further mechanistic studies are necessary to validate their function in post-TBI recovery and to explore their utility as clinical biomarkers or treatment targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.